Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1Rare Tumour 1HER2-positive Breast Cancer 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Breast Cancer With Brain Metastasis 1Brain Neoplasms 1

Interventions

Leucovorin 5Gemcitabine 5Fluorouracil 5Cisplatin 5durvalumab 3Oxaliplatin 3Capecitabine 3pembrolizumab 2lenvatinib 2S 1 (combination) 2Irinotecan 2Folfox protocol 2zimberelimab 1tocilizumab 1tislelizumab 1surufatinib 1regorafenib 1pemigatinib 1neratinib 1fludarabine 1donafenib 1dehydroftorafur 1Surgical Procedures, Operative 1Radiotherapy 1Proton Therapy 1Platinum 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Cholangiocarcinoma × neratinib × Clear all
NCT06519110 2024-07-25

CVL009-C2001

Convalife (Shanghai) Co., Ltd.

Phase 2 Not yet recruiting
60 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Salivary Gland Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡